CN101511384A - 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 - Google Patents

采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 Download PDF

Info

Publication number
CN101511384A
CN101511384A CNA200780032430XA CN200780032430A CN101511384A CN 101511384 A CN101511384 A CN 101511384A CN A200780032430X A CNA200780032430X A CN A200780032430XA CN 200780032430 A CN200780032430 A CN 200780032430A CN 101511384 A CN101511384 A CN 101511384A
Authority
CN
China
Prior art keywords
cell
cancer
carcinoma
dendritic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780032430XA
Other languages
English (en)
Chinese (zh)
Inventor
A·K·帕吕卡
J·F·班彻罗
N·塔丘特
S·伯克霍尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CN101511384A publication Critical patent/CN101511384A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA200780032430XA 2006-06-30 2007-06-29 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 Pending CN101511384A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30

Publications (1)

Publication Number Publication Date
CN101511384A true CN101511384A (zh) 2009-08-19

Family

ID=38895372

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780032430XA Pending CN101511384A (zh) 2006-06-30 2007-06-29 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞

Country Status (8)

Country Link
US (1) US20080031900A1 (enExample)
EP (2) EP2630968A1 (enExample)
JP (3) JP2009542714A (enExample)
KR (1) KR20090033375A (enExample)
CN (1) CN101511384A (enExample)
AU (1) AU2007269245B2 (enExample)
CA (1) CA2691346A1 (enExample)
WO (1) WO2008005859A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310709A (zh) * 2015-12-30 2019-02-05 细胞基因公司 T淋巴细胞生产方法和由此产生的t淋巴细胞
CN112646778A (zh) * 2012-12-28 2021-04-13 阿姆弗拉公司 免疫原性裂解物制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及药物组合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728772A1 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2547360A4 (en) * 2010-03-15 2013-11-20 Univ Pennsylvania SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS
KR20140054140A (ko) * 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
CN105999249A (zh) * 2011-10-20 2016-10-12 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
EP2787005A1 (en) * 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
US20180066229A1 (en) * 2015-03-17 2018-03-08 Shinshu University Method for preparing dendritic cells via non-adhesive culture using ifn
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
US12329807B2 (en) * 2018-01-18 2025-06-17 Meganano Biotech, Inc. Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
CA3132072A1 (en) * 2019-03-01 2020-09-10 Gritstone Bio, Inc. Selection of t cell receptors
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023013211A (ja) * 2021-07-15 2023-01-26 大日本印刷株式会社 細胞医薬品の提供方法、細胞医薬品用ラベルの作成方法、情報処理方法、プログラム、細胞医薬品、細胞医薬品容器および細胞医薬品提供システム
US12433915B2 (en) 2022-11-23 2025-10-07 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
ATE388237T1 (de) 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
ATE328607T1 (de) * 1998-01-16 2006-06-15 Biomira Usa Inc Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff
CA2321093A1 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
ATE552011T1 (de) * 2003-10-15 2012-04-15 Ist Superiore Sanita Kolorektal-karzinom-antigen
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646778A (zh) * 2012-12-28 2021-04-13 阿姆弗拉公司 免疫原性裂解物制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及药物组合物
CN109310709A (zh) * 2015-12-30 2019-02-05 细胞基因公司 T淋巴细胞生产方法和由此产生的t淋巴细胞

Also Published As

Publication number Publication date
US20080031900A1 (en) 2008-02-07
JP2013177430A (ja) 2013-09-09
CA2691346A1 (en) 2008-01-10
AU2007269245A1 (en) 2008-01-10
JP2016041725A (ja) 2016-03-31
EP2630968A1 (en) 2013-08-28
EP2037957A2 (en) 2009-03-25
KR20090033375A (ko) 2009-04-02
EP2037957A4 (en) 2010-09-08
JP2009542714A (ja) 2009-12-03
WO2008005859A3 (en) 2008-11-20
WO2008005859A2 (en) 2008-01-10
JP6134763B2 (ja) 2017-05-24
AU2007269245B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
Palucka et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
Panelli et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
Palucka et al. Designing vaccines based on biology of human dendritic cell subsets
Palucka et al. Recent developments in cancer vaccines
Jefford et al. The use of dendritic cells in cancer therapy
Li et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
Reardon et al. The development of dendritic cell vaccine-based immunotherapies for glioblastoma
Sheng et al. Dendritic cells: activation and maturation-applications for cancer immunotherapy
Wu et al. Hsp70-like Protein 1 fusion protein enhances induction of carcinoembryonic antigen–specific CD8+ CTL response by dendritic cell vaccine
Nencioni et al. Cellular immunotherapy with dendritic cells in cancer: current status
US20080171023A1 (en) Method to increase class i presentation of exogenous antigens by human dendritic cells
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO1998033527A2 (en) Cancer immunotherapy with semi-allogeneic cells
WO2014161887A1 (en) Targeted cancer immune therapy
Tamir et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors
Delluc et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response
Wang et al. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes
EP3350318B1 (en) Methods relating to activated dendritic cell compositions for subjects with advanced cancers
Weigel et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
Kim et al. Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo
Kim et al. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I–mediated antitumor immunity
Dehghan-Manshadi et al. Preventive cancer vaccination with P5 HER-2/neo-derived peptide‐pulsed peripheral blood mononuclear cells in a mouse model of breast cancer
Koido et al. Cancer immunotherapy by fusions of dendritic cells and tumor cells
Dao et al. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090819